Epigenetic therapy in non-small-cell lung cancer: Targeting DNA methyltransferases and histone deacetylases
Carcinoma, Non-Small-Cell Lung
DNA Modification Methylases
Histone Deacetylase Inhibitors
Combinatorial epigenetic therapy has demonstrated encouraging clinical activity, but many relevant questions remain. Global strategies influencing the epigenome may have both positive and potential negative long-term effects on cancer progression. Further clinical investigation of this approach, including exploratory studies to define predictive biomarkers, is warranted.